regulatory
confidence high
sentiment negative
materiality 0.85
PTC Therapeutics withdraws Translarna NDA resubmission after FDA cites insufficient efficacy data
PTC THERAPEUTICS, INC.
- Withdrew NDA resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy.
- FDA feedback indicated data unlikely to meet substantial evidence of effectiveness threshold.
- CEO Matthew Klein expressed disappointment after more than two decades of development efforts.
- No path to FDA approval for Translarna in the U.S. at this time.
- PTC Therapeutics (PTCT) shares potential negative impact from this regulatory setback.